News from Cancer Discovery

• Siglec-15: An Attractive Immunotherapy Target
  NC318 safe and well tolerated; single-agent efficacy seen in phase I trial.
• Free Article | Tucatinib Impresses in HER2-Positive Breast Cancer
  Topline results suggest that the TKI inhibitor extends OS, PFS—and has activity in patients with brain metastases.
• Oncology Drug Shortages Persist
  Inadequate vincristine supply highlights the need for strategies to avoid or mitigate a dearth of lifesaving therapies.